AbbVie Inc (ABBV NYSE) stock market data APIs
$204.8136
3.89(1.9%)
as of March 19, 2026
Try our APIs with
free plan!
AbbVie Inc Financial Data Overview
Price chart is built with
Anychart
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Prev. Close
204.8136
Open
208.7002
High
211.4646
Low
204.0402
52 wk Range
159.0544-241.1178
Market Cap
364 649 M
P/E Ratio
87.0169
Shares Outstanding
1 768 M
Revenue
61 160 M
EPS
2.71
Dividends (Yield)
0.0319
Beta
0.334
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with AbbVie Inc (top by weight)
Ticker
100-day Price Change
Weight
HDLB.US
ETRACS Monthly Pay 2xLeveraged US High Dividend Low Volatility ETN Series B
2.72
(18.69%)
9.80
W311.XETRA
HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Accumulating
-0.48
(-7.04%)
7.47
W311.F
HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Accumulating
-0.57
(-8.41%)
7.47
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get AbbVie Inc data using free add-ons & libraries
Get AbbVie Inc Fundamental Data
AbbVie Inc Fundamental data includes:
- Net Revenue: 61 160 M
- EBITDA: 29 254 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-04
- EPS/Forecast: 3.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AbbVie Inc News
New
The Market’s Favorite Active ETF Was Made for This Moment. Is It Delivering?
JPMorgan Equity Premium Income ETF (JEPI) is built to cushion volatility, but investors may find stronger returns in defensive sectors and dividend funds. Continue Reading
'Not Trying To Beat The Market Anymore' — Early Retiree Shares 6 Stocks Generating $91,000 in Dividend Income, Says He's 'Enjoying The Money'
Early retirement is gaining popularity among young Americans. Many are using safe dividend stocks and funds to cover their expenses and escape the 9-to-5 grind. Last month, a Reddit user shared a mil...
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
Shares of Protagonist Therapeutics PTGX have gained nearly 7% over the past week. The upside came after the company announced that the FDA had approved its partner, Johnson & Johnson JNJ’s icotrokin...
Is AbbVie (ABBV) Quietly Rewiring Its Immunology Edge With Alloy’s Antibody Discovery Deal?
On 17 March 2026, Alloy Therapeutics announced a multi-year agreement giving AbbVie access to its ATX-Gx-based antibody discovery platform, with Alloy receiving an upfront payment and additional compe...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
